首页> 外文OA文献 >Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial

【2h】

Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial

机译：评估贝伐单抗联合铂类化学疗法一线治疗的晚期非鳞状非小细胞肺癌晚期贝伐单抗超越疾病进展的持续性的随机IIIb期试验：AvaALL的治疗原理和方案动态（MO22097）试用版

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Gridelli Cesare; Bennouna Jaafar; de Castro Javier; Dingemans Anne-Marie C.; Griesinger Frank; Grossi Francesco; Rossi Antonio; Thatcher Nick; Wong Elaine K.; Langer Corey;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. [J] . Gridelli C, Bennouna J, de Castro J, Clinical lung cancer . 2011,第6期

机译：IIIb期随机试验评估了贝伐单抗联合铂类化疗一线治疗后晚期非鳞状非小细胞肺癌晚期贝伐单抗在疾病进展中的延续性：AvaALL的治疗原理和方案动态（MO22097）试用。
2. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
3. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) [J] . Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第3期

机译：贝伐单抗和厄洛替尼（BE）一线治疗晚期非鳞状非小细胞肺癌（NSCLC）（IIIB / IV期），然后在疾病进展时进行铂类化疗（CT）：一项多中心II期试验（ SAKK 19/05）
4. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) [O] . Masayuki Takeda, Isamu Okamoto, Takeharu Yamanaka, 2012

机译：贝伐单抗治疗对疾病进展以外的影响：铂类化疗加贝伐单抗治疗晚期非鳞状非小细胞肺癌患者中多西他赛联合或不联合贝伐单抗的II期随机研究（WJOG 5910L）
5. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial [O] . Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, 2016

机译：Bevacizumab超越疾病进展在先进的非小细胞肺癌中饲养贝伐单抗加上化疗后，（西日本肿瘤组5910L）：开放标签，随机，第2期试验

著录项

相似文献

相关主题

期刊订阅